Cybin Secures New U.S. Patent for DMT-Based Anxiety Treatment Program, Bolstering Phase 2 Clinical Development
Stock Information for Cybin Inc.
Loading
Please wait while we load your information from QuoteMedia.
Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.